Jefferies: Eli Lilly shows "noteworthy" weight reduction with next-generation obesity drug
A race to the obesity market is taking place – and US-based Eli Lilly has shown a ”noteworthy” body weight reduction in a phase II trial of drug candidate retatrutide, says investment bank Jefferies.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Eli Lilly boasts big weight-loss in study of GLP-1 tablet
For subscribers
Zealand Pharma presents phase I data from weight-loss drug
For subscribers